Verition Fund Management LLC Arvinas, Inc. Transaction History

Verition Fund Management LLC

$17.4 Billion
Q3 2024

A detailed history of Verition Fund Management LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 38,631 shares of ARVN stock, worth $737,079. This represents 0.01% of its overall portfolio holdings.

Number of Shares

38,631

Previous 91,351 57.71%

Holding current value

$737,079

Previous $2.43 Million 60.88%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$23.66 - $32.73 $1.25 Million - $1.73 Million	-52,720 Reduced 57.71%	38,631 $951,000
Q2 2024 Aug 14, 2024	BUY	$24.46 - $40.4 $386,468 - $638,320	15,800 Added 20.91%	91,351 $2.43 Million
Q1 2024 May 14, 2024	BUY	$36.38 - $52.31 $2.75 Million - $3.95 Million	75,551 New	75,551 $3.12 Million
Q3 2023 Nov 14, 2023	BUY	$19.64 - $28.21 $2.84 Million - $4.08 Million	144,697 Added 203.24%	215,893 $4.24 Million
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $1.21 Million - $1.75 Million	55,682 Added 358.91%	71,196 $1.77 Million
Q1 2023 May 15, 2023	BUY	$26.15 - $37.26 $405,691 - $578,051	15,514 New	15,514 $423,000
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $266,008 - $391,999	-3,634 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$60.45 - $84.26 $1.84 Million - $2.56 Million	-30,365 Reduced 89.31%	3,634 $280,000
Q1 2021 May 18, 2021	SELL	$58.19 - $91.37 $2.4 Million - $3.77 Million	-41,268 Reduced 54.83%	33,999 $2.25 Million
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $1.52 Million - $6.39 Million	75,267 New	75,267 $6.39 Million
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $1.48 Million - $2.34 Million	-64,259 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$29.88 - $56.74 $1.92 Million - $3.65 Million	64,259 New	64,259 $2.16 Million

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.

Account

Verition Fund Management LLC Arvinas, Inc. Transaction History